Greece also relies heavily on tourist receipts, and launched a new campaign for foreign tourists titled “Destination Greece, Health First.” A slick, 30-second video said: “Behind your every ideal experience, there is a complete protocol for your safety in action.” But after a recent spike in cases was traced to Serbian holidaymakers, Greece barred entry to Serbian nationals.Europe is the world’s leading tourist destination, and virtually every country made promises to get its hospitality sector — which effectively shuttered during the worst of the pandemic — back on track. But that means risking a return of the virus, which made its way through airports and train stations in the first place.”It is travel that has spread the virus across the world and brought it to our shores,” says a report published by SAGE, an independent group of U.K. scientists. “Were Britain and Ireland willing, and able, to take advantage of being islands, it would greatly help in defeating the virus and returning our lives and our economy to something like normality,” the report says.In Belgium, a group of epidemiologists told the public: “Don’t travel, or at least not far.”A spike in Catalonia — also a tourist hot spot — prompted Wallonia’s Minister-President Elio Di Rupo to consider possible quarantines and restrictions — all while creating a “vast” campaign promoting Wallonia as a tourist destination.This article is part of POLITICO’s premium policy service: Pro Mobility. From the digitization of the automotive sector to aviation policy, logistics and more, our specialized journalists keep you on top of the topics driving the Mobility policy agenda. Email [email protected] for a complimentary trial. Voiced by Amazon Polly Welcome to Schrödinger’s tour package, where sun-seekers are simultaneously being told to travel and discouraged from doing so because of the coronavirus danger.Take Belgium. On the day it signed on to an EU-approved list of 14 non-EU countries whose residents can enter the Schengen area — meant to open the Continent to tourists and travelers from safe countries — its interior ministry sent out an email, seen by POLITICO, notifying the industry that it will impose travel restrictions on all travelers coming to Belgium from outside Europe.The restrictions, which include a blanket ban on nonessential travel and a 14-day quarantine for everyone who does have the right to land, were made at a time when Belgium — and Europe — is trying to salvage the tourist season and actively encouraging people to travel. Also On POLITICO Europe’s country-by-country travel restrictions explained By POLITICO Swedish epidemiologist admits to flaws in country’s coronavirus response By Laurenz Gehrke There are mixed messages elsewhere too.The U.K.’s Foreign and Commonwealth Office recommends British nationals “against all but essential international travel,” but has made exceptions for dozens of countries. The Department for Transport issued a list where British nationals can go on holiday and won’t be subject to a 14-day quarantine on their return.People sticking to their holiday plans are subject to mandatory masks, possible quarantines, contact-tracing paperwork, occasional airport tests and other measures — even as Mediterranean countries are courting visitors.”There is so much uncertainty out there that we need to stay flexible, which is terrible news for an industry that needs predictability more than anything else,” said Andrew Charlton, managing director at consultancy Aviation Advocacy.Portuguese Prime Minister António Costa was aggrieved that his country was excluded from the U.K.’s safe list of countries, and is anxious to convince Brits that it’s safe to visit. He tweeted a chart comparing the U.K.’s case rate with that of Portugal’s Algarve district, a popular tourist destination, which showed the U.K.’s being much higher.”You are welcome to spend a safe holiday in Algarve!” he said. That in turn led to criticism that opening to the U.K. might bring more cases of the virus to Portugal. Press play to listen to this article
Palm Beach Titans defeat Southshore by 49 runs via the Duckworth Lewis Stern method, while St. Bess and Tropics United get by Lauderhill Jammers and St. Lucie by 32 and 25 runs respectively in the South Florida Cricket Alliance T20 last Sunday.In Port St. Lucie at Girl Scout Friendship Park, St. Lucie vs. Tropics United.Tropics batting first, made 143 for 6 from their allotted 20 overs. Philerm Davis topscored with 62, Ernie joseph 26, St Christopher Brown 13 and Bert Davis 12. Bowling for St. Lucie, Charles Reid and Glen Scott each taking a wicket for 13 and 22 respectively, while three wickets went via run out.Replying, St. Lucie could only manage to make 118 for 6 from their 20 overs. Charles Reid got 45 Not Out, Neil Greene 21 and Richard Louis and Glen Scott 17 each. The main wicket takers for Tropics United are Marcel Graham 3 for 33 and Mohammed Siddique 2 for 12. Tropics won by 25 runs.Lauderhill Jammers vs. St. Bess at the Lauderhill Sports Park.St Bess 192 for 6; Ricky Nayar and O’Brian Jones 42 each, Antonio Scott 27 and Atul Iyer 23. The wicket takers for Lauderhill Jammers were, David Brathwaite 2 for 22 and Aadam Khan 2 for 29.In Reply, Lauderhill Jammers made 160 for 4 from 20 overs, Mark Johnson topscored 44 Not Out, Sheldon Irvin and Elvis Watson 24 each, while Timmy Surujbally chipped in with 21. Bowling for St. Bess, Kemar Blake got 2 for 35, giving St. Bess victory by 32 runs.At John Prince Park, Palm Beach Titans vs. Southshore.Palm Beach Titans 182 for 1, Sachith Kongahakotiwi 108 Not out (10sixes, 3fours) and Andres Fraser 48. Byron Bowes took the lone wicket to fall for 25 runs.Southshore was 27 for 4 when rain intervened, giving Palm Beach Titan victory by 49 runs via the Duckworth Lewis Stern Method. The leading wicket taker for Palm beach was Leju Gevarghese with 3 for 14 from 3.5 overs.
Last Updated: 29th February, 2020 11:27 IST Devers Likely To Be Even Bigger Part Of Boston Offense third baseman Rafael Devers already has parts of three seasons and a World Series championship on his resume. And after finishing 12th in American League MVP voting in his breakout 2019, the Red Sox believe Devers hasn’t approached his ceiling yet. His baby face and near constant smile may make him appear younger than his 23 years. But third baseman Rafael Devers already has parts of three seasons and a World Series championship on his resume. And after finishing 12th in American League MVP voting in his breakout 2019, the Red Sox believe Devers hasn’t approached his ceiling yet.Devers hit .311 with 32 homers, 115 RBIs, an AL-leading 54 doubles, and a major league-leading 90 extra-base hits last season. He led the Red Sox in games played (156), hits (201), and average. With the departure of Mookie Betts in a trade to the Los Angeles Dodgers, Devers will be an even bigger part of Boston’s offense this season.“Especially as much as he’s improved his game defensively, he’s a huge part,” said manager Ron Roenicke. “The bat is good because of especially where it plays in the lineup and how we can push that lineup deeper makes it tough to pitch to us.”Roenicke expects to bat Devers second this season, behind likely lead-off hitter Andrew Benintendi, where Devers had much of his success last season after taking over the spot in late June.“Wherever the team feels I should be batting in the lineup, I’ll do whatever they say,” said Devers, who made his 2020 spring debut Friday. “But obviously I had a lot of success batting in the two hole last year. It’s not going to change my approach either way. I’m going to still do what I have to do, go out there and work hard.”From May through August, there weren’t many hitters hotter than Devers last season. How much more can Boston expect from him offensively?“It’s hard to say that you can see more than I saw for four straight months last year,” Roenicke said. “Four straight months was as good as anybody you could be in baseball as far as squaring up a baseball when you needed him. When we needed a good at-bat from him, for four straight months we saw a good at-bat. Maybe it was a lineout, but it was a good at-bat. And it was gaps and it was everything, so it’s pretty hard to think of anybody doing that for six months. He had a fabulous year offensively when you look at even just the total numbers, but I know what I saw for four straight months was amazing.”With Betts gone there will be big expectations for Devers. Former Red Sox slugger David Ortiz, though, only needs Devers to do what he did last season.“I saw more than 250 at-bats coming out of him (last year),” said Ortiz. “And I was saying, ‘Bro, I’m telling you this guy is on another level.’Devers knows what will be expected of him this season. But, he’s not feeling pressure to replace Betts, the 2018 AL MVP.“I don’t feel any pressure at all,” he said. “We have a great team. We have a lot of talent on this team. We have (Alex) Verdugo, we have (Benintendi), we have (Xander) Bogaerts, and J.D. (Martinez). There’s a bunch of guys that we have. So, we know we have to step our game up. So, obviously with Mookie because we know he’s a superstar but we don’t feel any pressure because we know the type of team we have and we’ll be ready for this coming season.”(Picture Credit: pixabay) SUBSCRIBE TO US Written By LIVE TV COMMENT FOLLOW US WATCH US LIVE Associated Press Television News First Published: 29th February, 2020 11:27 IST
NEW YORK | A huge international effort involving more than 100 institutions and genetic tests on 200,000 people has uncovered dozens of signposts in DNA that can help reveal further a person’s risk for breast, ovarian or prostate cancer, scientists reported Wednesday.Vicki Gilbert sits on stone steps in Wiltshire, England in this undated photo made available by the family on Tuesday, March 26, 2013. In 2010, Gilbert was diagnosed with breast cancer and then found she carries the mutated BRCA1 gene which may make her pre-disposed to ovarian cancer. Gilbert decided to have ovaries removed to prevent the potential onset of further cancer, and her breast cancer is in remission. A huge international effort involving more than 100 institutions and genetic tests on 200,000 people has uncovered dozens of signposts in DNA that can help reveal further a persons risk for breast, ovarian or prostate cancer, scientists reported Wednesday, March 27, 2013. Its the latest mega-collaboration to learn more about the intricate mechanisms that lead to cancer. (AP Photo)It’s the latest mega-collaboration to learn more about the intricate mechanisms that lead to cancer. And while the headway seems significant in many ways, the potential payoff for ordinary people is mostly this: Someday there may be genetic tests that help identify women with the most to gain from mammograms, and men who could benefit most from PSA tests and prostate biopsies.And perhaps farther in the future these genetic clues might lead to new treatments.“This adds another piece to the puzzle,” said Harpal Kumar, chief executive of Cancer Research U.K., the charity which funded much of the research.One analysis suggests that among men whose family history gives them roughly a 20 percent lifetime risk for prostate cancer, such genetic markers could identify those whose real risk is 60 percent.The markers also could make a difference for women with BRCA gene mutations, which puts them at high risk for breast cancer. Researchers may be able to separate those whose lifetime risk exceeds 80 percent from women whose risk is about 20 to 50 percent. One doctor said that might mean some women would choose to monitor for cancer rather than taking the drastic step of having healthy breasts removed.Scientists have found risk markers for the three diseases before, but the new trove doubles the known list, said one author, Douglas Easton of Cambridge University. The discoveries also reveal clues about the biological underpinnings of these cancers, which may pay off someday in better therapies, he said.Experts not connected with the work said it was encouraging but that more research is needed to see how useful it would be for guiding patient care. One suggested that using a gene test along with PSA testing and other factors might help determine which men have enough risk of a life-threatening prostate cancer that they should get a biopsy. Many prostate cancers found early are slow-growing and won’t be fatal, but there is no way to differentiate and many men have surgery they may not need.Easton said the prospects for a genetic test are greater for prostate and breast cancer than ovarian cancer.Breast cancer is the most common malignancy among women worldwide, with more than 1 million new cases a year. Prostate cancer is the second most common cancer in men after lung cancer, with about 900,000 new cases every year. Ovarian cancer accounts for about 4 percent of all cancers diagnosed in women, causing about 225,000 cases worldwide.The new results were released in 13 reports in Nature Genetics, PLOS Genetics and other journals. They come from a collaboration involving more than 130 institutions in the United States, Europe, and elsewhere. The research was mainly paid for by Cancer Research U.K., the European Union and the U.S. National Institutes of Health.Scientists used scans of DNA from more than 200,000 people to seek the markers, tiny variations in the 3 billion “letters” of the DNA code that are associated with disease risk.The scientists found 49 new risk markers for breast cancer plus a couple of others that modify breast cancer risk from rare mutated genes, 26 for prostate cancer and eight for ovarian cancer. Individually, each marker has only a slight impact on risk estimation, too small to be useful on its own, Easton said. They would be combined and added to previously known markers to help reveal a person’s risk, he said.A genetic test could be useful in identifying people who should get mammography or PSA testing, said Hilary Burton, director of the PHG Foundation, a genomics think-tank in Cambridge, England. A mathematical analysis done by her group found that under certain assumptions, a gene test using all known markers could reduce the number of mammograms and PSA tests by around 20 percent, with only a small cost in cancer cases missed.Among the new findings:— For breast cancer, researchers calculated that by using all known markers, including the new ones, they could identify 5 percent of the female population with twice the average risk of disease, and 1 percent with a three-fold risk. The average lifetime risk of getting breast cancer is about 12 percent in developed countries. It’s lower in the developing world where other diseases are a bigger problem.— For prostate cancer, using all the known markers could identify 1 percent of men with nearly five times the average risk, the researchers computed. In developed countries, a man’s average lifetime risk for the disease is about 14 to 16 percent, lower in developing nations.—Markers can also make a difference in estimates of breast cancer risk for women with the BRCA1 or BRCA2 gene mutations. Such women are rare, but their lifetime risk can run as high as 85 percent. Researchers said that with the new biomarkers, it might be possible to identify the small group of these women with a risk of 28 percent or less.For patients like Vicki Gilbert of England, who carries a variation of the BRCA1 gene, having such details about her cancer risk would have made decision-making easier.Gilbert, 50, found out about her genetic risk after being diagnosed with the disease in 2009. Though doctors said the gene wouldn’t change the kind of chemotherapy she got, they suggested removing her ovaries to avoid ovarian cancer, which is also made more likely by a mutated BRCA1.“They didn’t want to express a definite opinion on whether I should have my ovaries removed so I had to weigh up my options for myself,” said Gilbert, a veterinary receptionist in Wiltshire. “…I decided to have my ovaries removed because that takes away the fear it could happen. It certainly would have been nice to have more information to know that was the right choice.”Gilbert said knowing more about the genetic risks of cancer should be reassuring for most patients. “There are so many decisions made for you when you go through cancer treatment that being able to decide something yourself is very important,” she said.Dr. Charis Eng, chair of the Genomic Medicine Institute at the Cleveland Clinic, who didn’t participate in the new work, called the breast cancer research exciting but not ready for routine use.Most women who carry a BRCA gene choose intensive surveillance with both mammograms and MRI and some choose to have their breasts removed to prevent the disease, she said. Even the lower risk described by the new research is worrisomely high, and might not persuade a woman to avoid such precautions completely, Eng said.___AP Medical Writer Maria Cheng contributed to this report from London.